Keros Therapeutics, Inc. — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Keros Therapeutics filed an 8-K on July 22, 2026, reporting Item 5.02 regarding departure of a director or officer and/or appointment of officers and compensatory arrangements. The filing provides no specific names, dollar amounts, equity grants, dates of departure, or other concrete details in the text provided.
Why this rating
Material facts omitted from filing text—no names, amounts, or dates disclosed. Cannot assess impact without specifics on who departed, role, severance, or replacement.
Extracted items
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.